Phase I study of Ustekinumab biosimilar.
Phase of Trial: Phase I
Latest Information Update: 16 May 2018
At a glance
- Drugs Ustekinumab (Primary)
- Indications Cancer; Inflammation
- Focus Adverse reactions
- 16 May 2018 New trial record
- 10 May 2018 According to the NeuClone media release, company planned this study is 2019.